Kurma Partners announces the final closing of its Kurma Diagnostics 2 (KDx2) fund at €83 million

Paris, 2 December 2021 - Kurma Partners exceeded its initial target and reached over €83 million for the final closing of its Kurma Diagnostics 2 (KDx2) vehicle, a pioneering healthtech investment fund in Europe. KDx2 is backed by prominent investors, including its existing investors, the European Investment Fund (EIF) with the support of InnovFin Equity and of the European Guarantee Fund (EGF), Fonds national d’amorçage 2 (the French Seed Fund), managed by Bpifrance on behalf of the French State, BNP Paribas, as well as new investors. These include three Belgian funds, SFPI-FPIM, Noshaq and Sambrinvest, in addition to Eurazeo, which recently increased its stake in the management company.

After a first closing in 2020 at €50 million, the KDx2 fund is now ahead of its initial target at €83 million. The new generation Kurma Diagnostics fund continues its predecessor’s investment strategy with minority stakes in European companies specialising in areas like developing digital therapies, advanced diagnostic tools and smart and connected medical objects.

With more than €500 million in assets under management and more than 45 investments made since its launch in 2009, Kurma Partners has developed strong expertise in financing healthcare innovation, from pre-seed to growth capital. Focusing on addressing unmet needs and developing new usages, the teams support companies developing medical treatments as well as hardware and software solutions aimed at improving the patient and caregiver journey thanks to their regulatory and technical knowledge.

With the support of its long-term as well as new investors, KDx2 aims to build a portfolio of some 15 innovative companies in the European Union. After its first closing in August 2020, KDx2 invested in four companies:

  • Mila, a pioneering company in the development of digital rehabilitation tools for children with special learning and language disabilities. Mila-Learn is the first therapeutic tool developed by the company in a clinical trial, which will involve 154 patients in France and will be seconded by an international clinical study.
  • Arkhn, a pioneer and leader in data infrastructure and interoperability, helps healthcare facilities to manage and enhance their data to better support patients, facilitate the work of caregivers and accelerate research. The company is currently working with major players such as AP-HP, Institut Curie and the Toulouse University Hospital.
  • Smartcatch, a CNRS spin-off, is developing a device with an innovative nanostructure filtration technology for collecting and characterising tumour cells circulating in the blood, to enable clinicians to better monitor cancer treatment and detect early metastasis and treatment resistance.
  • Omnidoc is a care coordination solution connecting hospital practitioners with their community-based counterparts. The solution seamlessly and securely enables the sharing of expertise among peers resulting in better patient care, lower overall costs and improved revenue management for healthcare facilities. With adoption growing fast, Omnidoc is currently deployed in some twenty hospitals and used by 5,000 doctors.

Download the pdf file